Virginia is currently home to 1858 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Platinum-resistant Ovarian Cancer, Cutaneous Squamous Cell Carcinoma
Register for Updates
The Influence of Different Mood States and Emotions on the Physiologic, Metabolic, and Perceptual Responses to Feeding Before Exercise
NCT05217589
Recruiting
Many athletes anecdotally report modifying their nutritional intake before competition in order to avoid gut problems, but no studies have evaluated whether emotional state impacts tolerance to pre-exercise feeding. Therefore, this study will use movie clips (stressful, horror, and funny/amusing) to induce different mood states and emotions, which will be followed by ingestion of food before endurance running on a treadmill. In addition, metabolic and physiologic responses to mood induction will... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
10/31/2023
Locations: Human Performance Laboratory, Norfolk, Virginia
Conditions: Other Gastrointestinal Disorders, Cramp, Abdominal
Register for Updates
Safety and Tolerability of Intravenous Administration of ICVB-1042
NCT05904236
Recruiting
Study to evaluate the safety and tolerability of intravenous ICVB-1042
Gender:
All
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Next Oncology, Virginia, Fairfax, Virginia
Conditions: Patients With Advanced Solid Tumors
Register for Updates
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
NCT04786262
Recruiting
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/30/2023
Locations: VCU Medical Center, Richmond, Richmond, Virginia
Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Register for Updates
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038
Recruiting
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Virginia Cancer Specialists, PC, Gainesville, Virginia
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-small cell lung carcinoma [NSCLC], triple-negative breast cancer [TNBC]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecte... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Solid Tumor
Register for Updates
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02810704
Recruiting
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/30/2023
Locations: Anderson Orthopaedic Institute (VA), Alexandria, Virginia
Conditions: Pulmonary Embolism, Venous Thrombosis
Register for Updates
Health Education Approach to Lung Screening
NCT06070870
Recruiting
Evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (LCS), defined as undergoing a low dose computed tomography (LDCT)
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
10/27/2023
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Lung Cancer
Register for Updates
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925
Recruiting
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Dren Investigational Site, Charlottesville, Virginia
Conditions: LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous T-Cell Lymphoma - Category, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Indolent Chronic Lymphoproliferative Disorder (CLPD) (CD8+ or NK Derived) of the GI Tract, Other CD8+/NK Cell Driven Lymphoma Not Listed Above
Register for Updates
Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?
NCT04723862
Recruiting
The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism (HA), androgen-receptor blockade (spironolactone) alone normalizes sleep-wake luteinizing hormone (LH) pulse frequency (primary endpoint) and overall LH and follicle-stimulating hormone secretion (secondary endpoints).
Gender:
Female
Ages:
Between 10 years and 17 years
Trial Updated:
10/25/2023
Locations: Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia
Conditions: Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Register for Updates
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
NCT04511845
Recruiting
Phase I, open-label, multi-center study
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Locally Advanced or Metastatic Solid Tumors
Register for Updates
Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess?
NCT04075149
Recruiting
Adolescent girls with androgen excess have a higher rate of irregular periods and decreased ovulation rates compared to normal girls, and are considered at-risk for developing polycystic ovary syndrome (PCOS). This pilot study will look at whether giving spironolactone might improve ovulation rates in girls with androgen excess, ages 13-19. If this is true, spironolactone treatment to young girls might prevent PCOS from developing and avoid future infertility.
Gender:
Female
Ages:
Between 13 years and 19 years
Trial Updated:
10/25/2023
Locations: University of Virginia Center for Research in Reproduction, Charlottesville, Virginia
Conditions: Polycystic Ovary Syndrome, Puberty Disorders, Ovulation Disorder
Register for Updates